Dadgar Habibollah, Pashazadeh Ali, Norouzbeigi Nasim, Assadi Majid, Al-Balooshi Batool, Baum Richard P, Al-Ibraheem Akram, Haidar Mohamad, Beheshti Mohsen, Geramifar Parham, Vali Reza, Mohammadi Seyed, Dash Swagat, Malasani Vindhya, Cimini Andrea, Ricci Maria, Esmail Abdulredha A, Murad Sarah, Marafi Fahad, Treglia Giorgio, Khalaf Aysar Najeh, Anwar Farah M, Usmani Sharjeel, Omar Yehia, Muhsin Haider, Tyurin Igore E, Zakhary Andrew, Al-Sebaie Sahar, Cortes Danny Mena, AlHashim Maryam, Arabi Hossein, Zaidi Habib
Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.
Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany.
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
Radioligand therapy (RLT) has garnered significant attention due to the recent emergence of innovative and effective theranostic agents, which showed promising therapeutic and prognostic results in various cancers. Moreover, understanding the interaction between different types of radiation and biological tissues is essential for optimizing therapeutic interventions These concepts directly apply to clinical RLTs and play a crucial role in determining the efficacy and toxicity profile of different radiopharmaceutical agents. Personalized dosimetry is a powerful tool that aids in estimating patient-specific absorbed doses in both tumors and normal organs. Dosimetry in RLT is an area of active investigation, as our current understanding of the relationship between absorbed dose and tissue damage is primarily derived from external-beam radiation therapy. Further research is necessary to comprehensively comprehend this relationship in the context of RLTs. In the present review, we present a thorough examination of the involvement of Lu/Ac radioisotopes in the induction of direct and indirect DNA damage, as well as their influence on the initiation of DNA repair mechanisms in cancer cells of neuroendocrine tumors and metastatic prostate cancer. Current data indicate that high-energy α-emitter radioisotopes can directly impact DNA structure by causing ionization, leading to the formation of ionized atoms or molecules. This ionization process predominantly leads to the formation of irreparable and intricate double-strand breaks (DSBs). On the other hand, the majority of DNA damage caused by β-emitter radioisotopes is indirect, as it involves the production of free radicals and subsequent chemical reactions. Beta particles themselves can also physically interact with the DNA molecule, resulting in single-strand breaks (SSBs) and potentially reversible DSBs.
放射性配体疗法(RLT)由于近期出现了创新且有效的治疗诊断剂而备受关注,这些治疗诊断剂在各种癌症中显示出了有前景的治疗和预后结果。此外,了解不同类型辐射与生物组织之间的相互作用对于优化治疗干预至关重要。这些概念直接适用于临床RLT,并在确定不同放射性药物制剂的疗效和毒性特征方面发挥着关键作用。个性化剂量测定是一种强大的工具,有助于估计肿瘤和正常器官中患者特异性的吸收剂量。RLT中的剂量测定是一个活跃的研究领域,因为我们目前对吸收剂量与组织损伤之间关系的理解主要来自外照射放疗。有必要进行进一步研究,以便在RLT的背景下全面理解这种关系。在本综述中,我们全面考察了镥/锕放射性同位素在诱导直接和间接DNA损伤中的作用,以及它们对神经内分泌肿瘤和转移性前列腺癌细胞中DNA修复机制启动的影响。目前的数据表明,高能α发射体放射性同位素可通过引起电离直接影响DNA结构,导致形成离子化的原子或分子。这种电离过程主要导致形成无法修复且复杂的双链断裂(DSB)。另一方面,β发射体放射性同位素引起的大多数DNA损伤是间接的,因为它涉及自由基的产生和随后的化学反应。β粒子本身也可与DNA分子发生物理相互作用,导致单链断裂(SSB)和潜在的可逆性DSB。